Aurobindo Pharma said its subsidiary Auro Vaccines LLC entered into a pact to acquire certain business assets from Profectus BioSciences Inc USA for an upfront cash consideration of USD 11.29 million (around ₹80 crore) with potential earn-outs on achieving certain milestones."Our vaccine candidate underwent an evaluation by BIRAC (Biotechnology Industry Research Assistance Council, Department of BioTechnology).
BIRAC has evaluated our platform extensively and we have been informed that our vaccine has been shortlisted by BIRAC for funding initial development up," the city-based drug maker said in the annual report.The company is developing Pneumococcal Conjugate Vaccine (PCV).The global market size of the product is USD 6.2 billion.The.